Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

BACKGROUND: NEPA is a novel oral fixed-dose combination of netupitant (NETU), a new highly selective neurokinin-1 (NK(1)) receptor antagonist (RA) and palonosetron (PALO), a pharmacologically and clinically distinct 5-hydroxytryptamine type 3 (5-HT(3)) RA. This study was designed to determine the ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Hesketh, P. J., Rossi, G., Rizzi, G., Palmas, M., Alyasova, A., Bondarenko, I., Lisyanskaya, A., Gralla, R. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071755/
https://www.ncbi.nlm.nih.gov/pubmed/24608196
http://dx.doi.org/10.1093/annonc/mdu110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071755/
https://www.ncbi.nlm.nih.gov/pubmed/24608196
http://dx.doi.org/10.1093/annonc/mdu110

Ejemplares similares